<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331304</url>
  </required_header>
  <id_info>
    <org_study_id>2010P001442</org_study_id>
    <secondary_id>R01HS019371-01</secondary_id>
    <nct_id>NCT01331304</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness Study for Bipolar Disorder</brief_title>
  <official_title>Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of lithium and quetiapine for the
      treatment of individuals with bipolar disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mood stabilizers, medications that prevent future mood episodes, are the foundation for
      treatment of bipolar disorder. While all published bipolar disorder treatment guidelines
      recommend that pharmacotherapy should include mood stabilizers for long-term maintenance
      treatment, no randomized comparative effectiveness studies have examined the real-world
      advantages and disadvantages of the newer second generation antipsychotic (SGA) mood
      stabilizers compared to the classic mood stabilizers, such as lithium (Li). No studies have
      looked at the effectiveness of SGAs compared to mood stabilizers when used in the context of
      other medications required to manage bipolar patients, since bipolar disorder patients take a
      median of 3 medications for optimal outcomes. Quetiapine (QTP) is the most extensively
      studied, broadly efficacious and the most widely prescribed SGA for bipolar disorder. The
      classic mood stabilizer Li has the largest evidence base for treating bipolar disorder, but
      has been largely supplanted by the SGAs.

      Thus, this study compares symptomatic benefits and adverse effect burden between a QTP
      foundation with adjunctive personalized treatments (QTP+APT) and a mood stabilizer foundation
      consisting of Li with APT (Li+APT). APT will include any other medication needed with the
      following exceptions: the QTP+APT cannot receive Li and the Li+APT group cannot receive an
      antipsychotic. If, however, participants clinically require a switch to, or the addition of
      any other SGA or mood stabilizer, then those medications can be added as a rescue strategy
      that will be carefully recorded. Consistent with an effectiveness trial, participants will be
      able to continue in the study if they require a rescue treatment. The specific plan is a
      randomized, open, two arm, comparative effectiveness study of QTP+APT vs. Li+APT treatment
      for 6 months across 10 sites.

      In summary, this comparative effectiveness study compares fundamentally different acute and
      continuation treatments for bipolar disorder. The investigators address the key question of
      whether to use a prototypical mood stabilizing SGA (i.e., QTP) or the classical mood
      stabilizer Li as the foundational treatment in the context of other necessary adjunctive
      personalized treatments (APT).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-Efficacy Index (CGI-EI)</measure>
    <time_frame>Average 6 month score minus Average baseline score</time_frame>
    <description>The CGI-EI integrates benefits and harms and yields a score that can be compared across interventions. It is made up of 2 subscales: therapeutic effects and side effects. Each rating is on a scale from 1 to 4. To combine these two subscales into the CGI-EI we report as our primary outcome, we subtracted the side effects subscale from the therapeutic effects subscale. Thus, the CGI-EI we report ranges the integers from -3 to +3 (i.e. possible scores are -3,-2,-1,0,1,2,3). A score of -3 is the most burdensome side effect score (4) and the least therapeutic effect score (1) and a score of +3 is the least burdensome side effect score (1) and the highest therapeutic effect score (4). Higher CGI-EI signifies better outcome (minimal side effects, maximal therapeutic effect). Lower CGI-EI signifies worse outcome (maximal side effects, minimal therapeutic effect).To compute CGI-EI score, we subtract the side effect score from the therapeutic effect score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Necessary Clinical Adjustments</measure>
    <time_frame>6 Months</time_frame>
    <description>Necessary Clinical Adjustment (NCA): The Medication Recommendation Tracking Form was developed and successfully implemented in a previous study to capture recommended medication changes at each study visit 17. Clinicians record dosage changes, missed doses, new medications added or discontinued, and specify the reason for each change. Any change in psychotropic medications, or medications used to treat side effects, is coded along with the reason for the change. NCAs include those changes made for lack of effectiveness or intolerance, but not changes for planned dose titrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of Cardiovascular Disease - Framingham Risk Score</measure>
    <time_frame>Average baseline score minus Average 6 month score</time_frame>
    <description>The Framingham risk score captures the classic risk factors for cardiovascular disease, including age, sex, systolic blood pressure, total and high density lipoprotein cholesterol, diabetes mellitus, and smoking. The Framingham risk score is used as a simple predictive tool to determine 10-year (short term) risk for developing cardiovascular disease (CHD), with higher scores indicating higher risk. Established benchmarks exist for scores from 0 to 25--though it can exceed this value--that are meant to translate to the probability of developing heart disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Interval Follow up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)</measure>
    <time_frame>Average baseline score minus Average 6-month score</time_frame>
    <description>The LIFE-RIFT asses the extent to which psychopathology has impacted current functioning in work, household chores, interpersonal relationships with partner, family, and friends, recreational activities, and life, satisfaction, leisure activities and social relationships. Summary scores can range from 4 to 20, with higher scores indicating greater functional impairment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">482</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Li + APT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study participants will take lithium in addition to any other medications recommended by the study physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QTP + APT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>600-900mg per day over 6 months</description>
    <arm_group_label>Li + APT</arm_group_label>
    <other_name>Lithoboid, Eskalith</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>100-800mg a day over 6 months</description>
    <arm_group_label>QTP + APT</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meets DSM-IV criteria for BD I or II, which is the primary focus of treatment

          2. Able to give written informed consent

          3. Age &gt; to 18 years and &lt; 68 years

          4. Women of child bearing potential must agree to use adequate contraception (e.g. oral
             contraceptives, intrauterine device, barrier methods, or total abstinence from
             intercourse; Depo Provera is acceptable if it is started 3 months prior to
             enrollment), inform their doctor at the earliest possible time of their plans to
             conceive, and to understand the risks of lithium and other study treatments to the
             fetus and infant

          5. Currently symptomatic, as defined as a Clinical Global Impression - Bipolar Disorder
             Overall Severity (CGI-BP-S) score of at least 3 (mild)

          6. If currently taking an SGA, participants would be required to be willing to either
             discontinue or switch to QTP

          7. Willing to be randomized to either QTP+APT or Li+APT.

        Exclusion Criteria:

          1. Unwilling or unable to comply with study requirements

          2. If maintained on thyroid medication must be euthyroid for at least 1 month before
             Visit 1

          3. Patients who have had intolerable side effects with QTP or Li

          4. Patients whose clinical status requires inpatient care

          5. Drug/alcohol dependence within the past 30 days

          6. Pregnancy as determined by urine pregnancy test or breastfeeding

          7. History of nonresponse to Li at a serum level of ≥ 1.0 mEq/L ≥ 8 weeks

          8. History of nonresponse to QTP at doses of at least 600 mg ≥ 8 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew A Nierenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Center of HOPE</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2011</study_first_posted>
  <results_first_submitted>January 8, 2014</results_first_submitted>
  <results_first_submitted_qc>May 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2014</results_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Andrew A. Nierenberg, MD</investigator_full_name>
    <investigator_title>Director of Research, Bipolar Clinic and Research Program</investigator_title>
  </responsible_party>
  <keyword>Bipolar disorder</keyword>
  <keyword>Comparative effectiveness trial</keyword>
  <keyword>Lithium</keyword>
  <keyword>Quetiapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Li + APT</title>
          <description>Study participants will take lithium in addition to any other medications recommended by the study physician.
Lithium: 600-1200mg per day over 6 months</description>
        </group>
        <group group_id="P2">
          <title>QTP + APT</title>
          <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.
Quetiapine: 100-800mg a day over 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Li + APT</title>
          <description>Study participants will take lithium in addition to any other medications recommended by the study physician.
Lithium: 600-1200mg per day over 6 months</description>
        </group>
        <group group_id="B2">
          <title>QTP + APT</title>
          <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.
Quetiapine: 100-800mg a day over 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="240"/>
            <count group_id="B2" value="242"/>
            <count group_id="B3" value="482"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="12.1"/>
                    <measurement group_id="B2" value="39.1" spread="12.2"/>
                    <measurement group_id="B3" value="38.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression-Efficacy Index (CGI-EI)</title>
        <description>The CGI-EI integrates benefits and harms and yields a score that can be compared across interventions. It is made up of 2 subscales: therapeutic effects and side effects. Each rating is on a scale from 1 to 4. To combine these two subscales into the CGI-EI we report as our primary outcome, we subtracted the side effects subscale from the therapeutic effects subscale. Thus, the CGI-EI we report ranges the integers from -3 to +3 (i.e. possible scores are -3,-2,-1,0,1,2,3). A score of -3 is the most burdensome side effect score (4) and the least therapeutic effect score (1) and a score of +3 is the least burdensome side effect score (1) and the highest therapeutic effect score (4). Higher CGI-EI signifies better outcome (minimal side effects, maximal therapeutic effect). Lower CGI-EI signifies worse outcome (maximal side effects, minimal therapeutic effect).To compute CGI-EI score, we subtract the side effect score from the therapeutic effect score.</description>
        <time_frame>Average 6 month score minus Average baseline score</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Li + APT</title>
            <description>Study participants will take lithium in addition to any other medications recommended by the study physician.
Lithium: 600-1200mg per day over 6 months</description>
          </group>
          <group group_id="O2">
            <title>QTP + APT</title>
            <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.
Quetiapine: 100-800mg a day over 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-Efficacy Index (CGI-EI)</title>
          <description>The CGI-EI integrates benefits and harms and yields a score that can be compared across interventions. It is made up of 2 subscales: therapeutic effects and side effects. Each rating is on a scale from 1 to 4. To combine these two subscales into the CGI-EI we report as our primary outcome, we subtracted the side effects subscale from the therapeutic effects subscale. Thus, the CGI-EI we report ranges the integers from -3 to +3 (i.e. possible scores are -3,-2,-1,0,1,2,3). A score of -3 is the most burdensome side effect score (4) and the least therapeutic effect score (1) and a score of +3 is the least burdensome side effect score (1) and the highest therapeutic effect score (4). Higher CGI-EI signifies better outcome (minimal side effects, maximal therapeutic effect). Lower CGI-EI signifies worse outcome (maximal side effects, minimal therapeutic effect).To compute CGI-EI score, we subtract the side effect score from the therapeutic effect score.</description>
          <units>Units on the scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.32" upper_limit="1.84"/>
                    <measurement group_id="O2" value="1.52" lower_limit="1.26" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the first co-primary aim, mixed-effects linear regression analyses compared the two intervention groups on the repeated assessments of the CGI-EI over 6 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <p_value_desc>Because this study has co-primary outcomes (CGI-EI and NCAs), the analyses of the treatment effect in the two primary hypotheses each involved a two-tailed alpha-level of 0.025.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Necessary Clinical Adjustments</title>
        <description>Necessary Clinical Adjustment (NCA): The Medication Recommendation Tracking Form was developed and successfully implemented in a previous study to capture recommended medication changes at each study visit 17. Clinicians record dosage changes, missed doses, new medications added or discontinued, and specify the reason for each change. Any change in psychotropic medications, or medications used to treat side effects, is coded along with the reason for the change. NCAs include those changes made for lack of effectiveness or intolerance, but not changes for planned dose titrations.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Li + APT</title>
            <description>Study participants will take lithium in addition to any other medications recommended by the study physician.
Lithium: 600-1200mg per day over 6 months</description>
          </group>
          <group group_id="O2">
            <title>QTP + APT</title>
            <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.
Quetiapine: 100-800mg a day over 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Necessary Clinical Adjustments</title>
          <description>Necessary Clinical Adjustment (NCA): The Medication Recommendation Tracking Form was developed and successfully implemented in a previous study to capture recommended medication changes at each study visit 17. Clinicians record dosage changes, missed doses, new medications added or discontinued, and specify the reason for each change. Any change in psychotropic medications, or medications used to treat side effects, is coded along with the reason for the change. NCAs include those changes made for lack of effectiveness or intolerance, but not changes for planned dose titrations.</description>
          <units>Mean NCAs per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8" spread=".8"/>
                    <measurement group_id="O2" value=".9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the second co-primary, patient monthly rates of NCAs (determined by dividing total number of NCAs during follow-up by the length of follow-up – to account for attrition and resulting differential exposure time) for treatment groups were compared using a Wilcoxon rank-sum test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Cardiovascular Disease - Framingham Risk Score</title>
        <description>The Framingham risk score captures the classic risk factors for cardiovascular disease, including age, sex, systolic blood pressure, total and high density lipoprotein cholesterol, diabetes mellitus, and smoking. The Framingham risk score is used as a simple predictive tool to determine 10-year (short term) risk for developing cardiovascular disease (CHD), with higher scores indicating higher risk. Established benchmarks exist for scores from 0 to 25--though it can exceed this value--that are meant to translate to the probability of developing heart disease.</description>
        <time_frame>Average baseline score minus Average 6 month score</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Li + APT</title>
            <description>Study participants will take lithium in addition to any other medications recommended by the study physician.
Lithium: 600-900mg per day over 6 months</description>
          </group>
          <group group_id="O2">
            <title>QTP + APT</title>
            <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.
Quetiapine: 100-800mg a day over 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Cardiovascular Disease - Framingham Risk Score</title>
          <description>The Framingham risk score captures the classic risk factors for cardiovascular disease, including age, sex, systolic blood pressure, total and high density lipoprotein cholesterol, diabetes mellitus, and smoking. The Framingham risk score is used as a simple predictive tool to determine 10-year (short term) risk for developing cardiovascular disease (CHD), with higher scores indicating higher risk. Established benchmarks exist for scores from 0 to 25--though it can exceed this value--that are meant to translate to the probability of developing heart disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" lower_limit="-0.66" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.17" lower_limit="-0.21" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effects linear regression analyses compared the two intervention groups on the repeated collection of measures relevant to calculation of the Framingham Risk Score over 6 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>Analysis of this secondary outcome was not corrected for multiple comparisons. Therefore, the a priori threshold for statistical significance was set at 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longitudinal Interval Follow up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)</title>
        <description>The LIFE-RIFT asses the extent to which psychopathology has impacted current functioning in work, household chores, interpersonal relationships with partner, family, and friends, recreational activities, and life, satisfaction, leisure activities and social relationships. Summary scores can range from 4 to 20, with higher scores indicating greater functional impairment.</description>
        <time_frame>Average baseline score minus Average 6-month score</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Li + APT</title>
            <description>Study participants will take lithium in addition to any other medications recommended by the study physician.
Lithium: 600-900mg per day over 6 months</description>
          </group>
          <group group_id="O2">
            <title>QTP + APT</title>
            <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.
Quetiapine: 100-800mg a day over 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Longitudinal Interval Follow up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)</title>
          <description>The LIFE-RIFT asses the extent to which psychopathology has impacted current functioning in work, household chores, interpersonal relationships with partner, family, and friends, recreational activities, and life, satisfaction, leisure activities and social relationships. Summary scores can range from 4 to 20, with higher scores indicating greater functional impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.74" lower_limit="-4.29" upper_limit="-3.19"/>
                    <measurement group_id="O2" value="-3.61" lower_limit="-4.15" upper_limit="-3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effects linear regression analyses compared the two intervention groups on the repeated assessment of the LIFE-RIFT over 6 months</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <p_value_desc>Analysis of this secondary outcome was not corrected for multiple comparisons. Therefore, the a priori threshold for statistical significance was set at 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Li + APT</title>
          <description>Study participants will take lithium in addition to any other medications recommended by the study physician.
Lithium: 600-1200mg per day over 6 months</description>
        </group>
        <group group_id="E2">
          <title>QTP + APT</title>
          <description>Study participants will take quetiapine in addition to any other medications recommended by the study physician.
Quetiapine: 100-800mg a day over 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Issues</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism Treatment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Heroin Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Hospitalization reason unknown</sub_title>
                <description>Hospitalization reason unknown; unable to re-contact study participant</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Extreme Sedation Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Study Medication Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Adverse reaction to study medication: dizziness, disturbance in gait</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Staph Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Car/Bike Accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Broken Bones</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudoseizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="240"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Hospitalization</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="240"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema Outbreak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Laparoscopic Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="70" subjects_affected="58" subjects_at_risk="240"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Upset stomach/stomach pain/bloating</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="240"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="240"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="240"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive sleepiness/daytime somnolence</sub_title>
                <counts group_id="E1" events="96" subjects_affected="68" subjects_at_risk="240"/>
                <counts group_id="E2" events="249" subjects_affected="186" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="240"/>
                <counts group_id="E2" events="58" subjects_affected="51" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Increased Weight</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="240"/>
                <counts group_id="E2" events="55" subjects_affected="45" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="240"/>
                <counts group_id="E2" events="56" subjects_affected="55" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Increased Thirst</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Restless/fidgety (akathisia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="240"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="69" subjects_affected="63" subjects_at_risk="240"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Stiffness/muscle aches</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="240"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Weakness/muscle fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="240"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Muscle twitching (myoclonus)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="61" subjects_affected="48" subjects_at_risk="240"/>
                <counts group_id="E2" events="43" subjects_affected="33" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Memory/concentration problems</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="240"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheaded</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="240"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Urinary Frequency</sub_title>
                <counts group_id="E1" events="33" subjects_affected="32" subjects_at_risk="240"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory infection or other cold-like symptoms</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="240"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair Loss</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="240"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew Nierenberg</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-0837</phone>
      <email>anierenberg@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

